The “bottleneck” of current gene therapy approaches is the lack of an efficient gene delivery system. Retroviral vectors have been very useful for ex vivo gene delivery, but suffer two major ...

Oxford Biomedica, a prominent gene and cell therapy company, reported significant revenue growth alongside strategic ...

1996a) (Naldini et al., 1996b) , the vector pCMVΔR8.2 supplies all but the HIV envelope in trans, the vector pMD.G is used to produce the VSV-G pseudotype, while the transgene (lac Z) is inserted into ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Tectonic Therapeutic (TECX – Research Report). The ...

Discover Lyell Immunopharma's groundbreaking patent for EGFR-derived polypeptides, enhancing cancer treatment through innovative nucleic acid technologies and engineered T cells.

Oxford Biomedica plc ( OTCPK:OXBDF) Q2 2024 Earnings Conference Call September 23, 2024 8:00 AM ET Frank Mathias - Chief Executive Officer Sebastien Ribault - Chief Business Officer Lucinda Crabtree - ...

Discover how Oxford BioMedica's new patent enhances viral vector production efficiency with a novel nucleic acid sequence that regulates therapeutic protein translation.

Co-expressing NPY and its inhibitory receptor Y2 in excitatory hippocampal cells allows inhibitory autoregulation of ...

Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the ...

Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company’s cost structure ...

To address the unmet need for a cure for RTT, the therapeutic potential of adult Neural Precursor Cells (NPCs) was ...